What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence

Rachel Hu, Daniel J. George, Tian Zhang

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Prostate cancer is the most common cancer in men and the second most deadly. About one-third of patients with prostate cancer will develop metastatic disease. We discuss the six United States Food and Drug Administration (FDA) approved treatments for metastatic castrate-resistant prostate cancer (mCRPC) with a strong focus on sipuleucel-T. Sipuleucel-T is the first immunotherapy shown to improve survival in asymptomatic or minimally-symptomatic mCRPC. Herein, we discuss the proposed mechanism of sipuleucel-T and its synthesis. We describe in detail the three randomized controlled trials (RTCs) that led to its approval. We also compiled the newest research regarding use of sipuleucel-T with other agents and in different patient populations. Finally, we discuss the current ongoing trials.

Original languageEnglish (US)
Pages (from-to)272-278
Number of pages7
JournalTherapeutic Advances in Urology
Volume8
Issue number4
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Keywords

  • metastatic castration-resistant prostate cancer
  • prostate cancer
  • PROvenge
  • sipuleucel-T

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence'. Together they form a unique fingerprint.

Cite this